Our Research Projects
A prospective, multicenter, randomized comparison of Hydrus TM versus IStent for reducing intraocular pressure in primary open-angle glaucoma.
Compare the new Hydrus implant to the ability of the IStent (the standard implant) to reduce the pressure in your eye.
A randomized, prospective, multicenter, comparative trial to assess the safety and efficacy of the Hydrus implant in lowering intraocular pressure in patients with glaucoma undergoing cataract surgery.
To determine if a study device, the Hydrus IVANTIS implant, can be safely implanted in your eye and if it can reduce the pressure in your eye after cataract removal and an intraocular lens (IOL) has been implanted in your eye.
A 12-month, multicenter, randomized, double-blind, active-controlled, parallel-group study to compare the safety of AR-13324 Ophthalmic Solution 0.02% QD and BID versus timolol maleate 0.5% twice daily in patients with elevated intraocular pressure.
To compare the safety of AR13324 ophthalmic solution 0.02% with that of a commercially available timolol maleate ophthalmic solution 0.5% for lowering intraocular pressure in patients with glaucoma or ocular hypertension (increased eye pressure).
Efficacy and safety of extended-release bimatoprost in patients with open-angle glaucoma or ocular hypertension.
To examine the safety (safety) and effectiveness of two different amounts of extended-release bimatoprost compared to treatment with eye drops containing 0.5% timolol in reducing eye pressure in patients with glaucoma or high eye pressure. Timolol 0.5% is an approved medication for lowering eye pressure. Sustained-release bimatoprost is a very small implant that is biodegradable and contains bimatoprost. Bimatoprost extended release is placed inside a chamber of the eye.
Additive effect of combination therapy of brinzolamide 1% and brimonidine 0.2% fixed dose given twice daily as add-on therapy to a prostaglandin analogue.
To demonstrate the ability of a fixed-dose SIMBRINZA™ combination therapy to reduce intraocular pressure in research participants also treated with a prostaglandin analogue such as TRAVATAN® 0.004%, LUMIGAN® 0.01%, or XALATAN® 0.005% compared the effect and ability of prostaglandin analogue therapy used alone to reduce intraocular pressure.